AU703431B2 - Benzimidazole derivatives having dopaminergic activity - Google Patents

Benzimidazole derivatives having dopaminergic activity Download PDF

Info

Publication number
AU703431B2
AU703431B2 AU23510/95A AU2351095A AU703431B2 AU 703431 B2 AU703431 B2 AU 703431B2 AU 23510/95 A AU23510/95 A AU 23510/95A AU 2351095 A AU2351095 A AU 2351095A AU 703431 B2 AU703431 B2 AU 703431B2
Authority
AU
Australia
Prior art keywords
disorders
piperazin
fluoro
phenyl
propan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU23510/95A
Other languages
English (en)
Other versions
AU2351095A (en
Inventor
William S. Faraci
Anton F. J Fliri
Brian T. O'neill
Mark A Sanner
Stevin H. Zorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2351095A publication Critical patent/AU2351095A/en
Application granted granted Critical
Publication of AU703431B2 publication Critical patent/AU703431B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
AU23510/95A 1994-08-05 1995-05-18 Benzimidazole derivatives having dopaminergic activity Ceased AU703431B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28657694A 1994-08-05 1994-08-05
US08/286576 1994-08-05
US29800594A 1994-08-30 1994-08-30
US08/298005 1994-08-30
PCT/IB1995/000378 WO1996004250A1 (en) 1994-08-05 1995-05-18 Benzimidazole derivatives having dopaminergic activity

Publications (2)

Publication Number Publication Date
AU2351095A AU2351095A (en) 1996-03-04
AU703431B2 true AU703431B2 (en) 1999-03-25

Family

ID=26963924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23510/95A Ceased AU703431B2 (en) 1994-08-05 1995-05-18 Benzimidazole derivatives having dopaminergic activity

Country Status (20)

Country Link
EP (1) EP0775118B1 (enExample)
JP (1) JP3004727B2 (enExample)
KR (1) KR970704698A (enExample)
AT (1) ATE242220T1 (enExample)
AU (1) AU703431B2 (enExample)
BR (1) BR9503572A (enExample)
CA (1) CA2196769C (enExample)
CO (1) CO4410330A1 (enExample)
DE (1) DE69530988T2 (enExample)
DK (1) DK0775118T3 (enExample)
ES (1) ES2201105T3 (enExample)
FI (1) FI970469L (enExample)
IL (1) IL114754A0 (enExample)
MX (1) MX9700959A (enExample)
NZ (1) NZ284851A (enExample)
PE (1) PE35796A1 (enExample)
PT (1) PT775118E (enExample)
TR (1) TR199500956A2 (enExample)
TW (1) TW306920B (enExample)
WO (1) WO1996004250A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704578B2 (en) * 1995-12-21 1999-04-29 Pfizer Inc. 2,7-substituted octahydro-pyrrolo{1,2-a}pyrazine derivatives
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
AU2152001A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S Phenylpiperazinyl derivatives
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
AU2689502A (en) * 2000-11-22 2002-06-03 Abbott Lab The use of selective dopamine d4 receptor agonists for treating sexual dysfunction
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2002100350A2 (en) * 2001-06-13 2002-12-19 The Regents Of University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
JP2005527530A (ja) * 2002-03-12 2005-09-15 ワイス キラル１，４−二置換ピペラジン
JP2004123562A (ja) * 2002-09-30 2004-04-22 Japan Science & Technology Corp 神経細胞死抑制作用を有する化合物を用いた医薬
JPWO2005080334A1 (ja) * 2004-02-23 2007-08-02 大日本住友製薬株式会社 新規ヘテロ環化合物
SG151299A1 (en) 2004-03-25 2009-04-30 Univ Michigan Gossypol co-crystals and the use thereof
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
JP6350535B2 (ja) * 2012-11-26 2018-07-04 シェンヤン ハイワン バイオテクノロジー カンパニー リミテッドＳｈｅｎｙａｎｇ Ｈａｉｗａｎｇ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ 含窒素ベンゾ複素五員環含窒素ベンゾ複素五員環ピペラジン又はピペリジン誘導体の用途
JP2016500084A (ja) * 2012-11-26 2016-01-07 リアオニン エミー バイオロジカル ファーマシューティカル カンパニー リミテッドＬｉａｏｎｉｎｇ Ｅｍｍｙ Ｂｉｏｌｏｇｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ 含窒素ベンゾ複素五員環基ピペリジン又はピペラジン誘導体及びその作製方法並びに薬剤組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017265A1 (de) * 1969-04-08 1970-10-15 A.H. Robins Company Inc., Richmond, Va. (V.St.A.) l-(omega-substituierte-Alkyl)-2mehtylbenzimidazole und Verfahren zu deren Herstellung
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2017265A1 (de) * 1969-04-08 1970-10-15 A.H. Robins Company Inc., Richmond, Va. (V.St.A.) l-(omega-substituierte-Alkyl)-2mehtylbenzimidazole und Verfahren zu deren Herstellung
EP0526434A1 (en) * 1991-07-30 1993-02-03 BOEHRINGER INGELHEIM ITALIA S.p.A. Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists

Also Published As

Publication number Publication date
MX9700959A (es) 1997-05-31
FI970469A7 (fi) 1997-04-04
ES2201105T3 (es) 2004-03-16
CA2196769C (en) 2002-10-08
DE69530988T2 (de) 2003-12-04
JP3004727B2 (ja) 2000-01-31
ATE242220T1 (de) 2003-06-15
DK0775118T3 (da) 2003-09-29
CA2196769A1 (en) 1996-02-15
TW306920B (enExample) 1997-06-01
JPH09510706A (ja) 1997-10-28
FI970469A0 (fi) 1997-02-04
PE35796A1 (es) 1996-10-01
CO4410330A1 (es) 1997-01-09
WO1996004250A1 (en) 1996-02-15
PT775118E (pt) 2003-10-31
BR9503572A (pt) 1996-04-30
EP0775118B1 (en) 2003-06-04
EP0775118A1 (en) 1997-05-28
NZ284851A (en) 1998-07-28
AU2351095A (en) 1996-03-04
IL114754A0 (en) 1995-11-27
FI970469L (fi) 1997-04-04
TR199500956A2 (tr) 1996-07-21
DE69530988D1 (de) 2003-07-10
KR970704698A (ko) 1997-09-06

Similar Documents

Publication Publication Date Title
AU703431B2 (en) Benzimidazole derivatives having dopaminergic activity
US8420829B2 (en) Processes for the preparation of bendamustine
US5576318A (en) Benzimidazolone derivatives
EP0765320B1 (en) Benzimidazolone derivatives with central dopaminergic activity
US7049335B2 (en) 3-azabicyclo[3.1.0]hexane derivatives
JPH10503501A (ja) 抗喘息、抗アレルギー、抗炎症及び免疫修飾作用を有するインドール、インダゾール、ピリドピロール及びピリドピラゾール誘導体
DE19834751A1 (de) Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
JPS6289679A (ja) ピペリジン誘導体
US5889010A (en) Benzimidazole derivatives having dopaminergic activity
KR100530208B1 (ko) 벤지미다졸 유도체
WO2001014342A1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2737630C2 (enExample)
AU602418B2 (en) Benzimidazole derivatives, their preparation and their application in therapeutics
US3449357A (en) 2-((2,6-substituted)phenoxymethyl)-2-imidazolines
US5254560A (en) 2-piperidinylpyrimidine-4-carboxamide derivatives, and their use in therapeutics
US6512000B1 (en) Aminocarbonyl-substituted benzimidazoles having tryptase-inhibitory activity
US5246939A (en) 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics
CZ154097A3 (en) Derivatives of 6-methoxy-1h-benzotriazole-5-carboxamide, process of their preparation and pharmaceutical compositions based thereon
US6780863B1 (en) Bis-basic compounds with tryptase-inhibitory activity
US5420130A (en) 2-aminopyrazine-5-carboxamide derivatives, their preparation and their application in therapeutics
KR810001892B1 (ko) 페닐 에틸 아민류의 제조방법
JPH01139563A (ja) ウレア誘導体
CZ336499A3 (cs) Benzimidazolové deriváty
PL175918B1 (pl) N-podstawione pochodne 3-azabicyklo/3.2.0/ heptanu
JPH08225571A (ja) ６−アルコキシ−１ｈ−ベンゾトリアゾール−５−カルボキサミド誘導体及びその中間体並びに該化合物を含有する医薬組成物

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired